Sanger sequencing on tumor samples after progression confirmed FGFR2-CLIP1 fusion in all samples, furthermore, whole-exome sequencing revealed 242 unique mutations to post progression and a FGFR2 kinase domain acquired mutation, FGFR2 N549H in a single liver tumor. This evidence concerns the gene CLIP1 and neoplasm.